Atheris Group
Azhar Rana, MD, currently serves as the President of Atheris Group, providing medical affairs and strategic communications support within the biotech, pharmaceutical, and healthcare sectors. With extensive experience in genetic neurodevelopmental and metabolic disorders, infectious diseases, immunological conditions, and cardio-metabolic disorders, Azhar has held various leadership roles including Chief Medical Officer and Strategic Advisor at MVMD, as well as a director position at SANSAR, a charitable organization focused on improving cardiovascular health in Canada's South Asian community. Previous appointments include significant roles at integrated medhealth communication and AstraZeneca, where responsibilities encompassed global clinical operations and medical affairs. Azhar's early career included impactful positions at Novo Nordisk, Bristol-Myers Squibb, and the NHS, where contributions spanned clinical development, regulatory affairs, and medical leadership across various therapeutic areas. Azhar’s educational credentials include an MBBS from Aga Khan University and a Certificate in Medicinal Plants from Cornell University.
This person is not in any teams
This person is not in any offices
Atheris Group
At Atheris, we specialize in providing comprehensive scientific communication consulting services to clients through the journey from pre-launch planning to post-launch success. By working with commercial and medical affairs teams, we develop and execute quality communication and engagement initiatives for internal and external audiences. Our team has extensive experience in rare, genetic and chronic diseases. We also provide in-house contract resource across different functions, including office and field Medical Affairs and Medical Information. With a deep understanding of the biotech and pharma sector, expertise in medical communications, and a wide network of industry professionals, our team of seasoned experts are dedicated to helping you achieve your goals and maximize your brand potential.